MMP9 and rosacea: Clinical trials in periodontitis, rosacea, and vascular inflammation consistently demonstrate reduced gingival crevicular fluid or plasma MMP-9, improved tissue stability, and lower inflammatory indices when sub-antimicrobial dose doxycycline (SDD) is added to standard care.